Jonas Wang | Chief Executive Officer/Chariman
StemCyte International

Jonas Wang, Chief Executive Officer/Chariman, StemCyte International

Dr. Jonas Wang is CEO/Chairman of StemCyte International Ltd (SIL).  Before joining SIL, he was a Partner of Sycamore Ventures focusing on life sciences and biotechnology investments in 2002-2014.  
Before joining Sycamore Ventures, Jonas was Vice President of Research and Technology at Johnson & Johnson Consumer Products and a Corporate Director of J&J Drug Delivery Technology Resource Center (TRC), responsible for new product technology, patent strategy, competitive intelligence, and new measurement methodology for skin and hair care franchise. Prior to that, he was an Associate Director of Basic Pharmaceutics, the Pharmaceutical Research Institute of Bristol-Myers Squibb Co.  In 2001, he had participated at the Congressional Business Summit in Washington, D. C., leading the group exploring emerging markets in America. 
Jonas has over 30 years of experience in pharmaceutical R&D management and business development.  He was also a member of J&J Consumer Product Worldwide L&A Committee and was the key driver for several major acquisitions. He has published extensively in drug delivery technology and received several major awards in his field, including the Johnson Medal, the highest technical achievement award at J&J, for one of his inventions: anti-wrinkle cream; the Distinguished Alumni awards from the National Defense Medical Center and College of Pharmacy, University of Iowa.  During his career with J&J, Jonas developed more than 10 core technologies, and filed more than 30 business-related patents.  
Jonas received his Ph.D. in Physical Pharmacy from College of Pharmacy, University of Iowa, USA in 1982 and B.S. Pharmacy degree from National Defense Medical Center in Taiwan, Republic of China.


Cord Blood Day 2- Thursday 17th May 2018 @ 10:15

The Commercialization of StemCyte International Ltd. and its operational challenge

  •     The success of StemCyte’s “Dual Track” business strategy! 
  •     The development of MonoNuclear Cells (UCBMNC) Platform Technology
  •     The Operational Challenge of Regenerative Cell Therapy  

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257